The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s
heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria …

Antimalarial drug resistance, in particular resistance to Plasmodium falciparum, challenges
the treatment and control of malaria. In this Review, we summarise evolving patterns of …

Malaria cases and deaths remain unacceptably high and are resurgent in several settings,
though recent developments inspire optimism. This includes the approval of the world's first …

Background Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin–
piperaquine is more effective than IPTp with sulfadoxine–pyrimethamine at reducing malaria …

One hundred and twenty-five million women in malaria-endemic areas become pregnant
each year (see Dellicour et al. PLoS Med 7: e1000221 [2010]) and require protection from …

Malaria remains one of the most preventable causes of adverse birth outcomes. Intermittent
preventive treatment in pregnancy (IPTp) with sulfadoxine–pyrimethamine is used to prevent …

Emergence and spread of resistance in Plasmodium falciparum to the frontline treatment
artemisinin-based combination therapies (ACTs) in the epicenter of multidrug resistance of …

Artemisinin-based combination therapies (ACTs) have become the mainstay for malaria
treatment in almost all malaria endemic settings. Artemisinin derivatives are highly potent …

One hundred twenty-five million pregnant women are at risk for contracting malaria, a
preventable cause of maternal and infant morbidity and death. Malaria parasites contribute …

Background 2· 6 million stillbirths occur annually worldwide. The association between
malaria in pregnancy and stillbirth has yet to be comprehensively quantified. We aimed to …